CA2123403C — Acyclic ethylenediamine derivatives as substance p receptor antagonists
Assigned to Pfizer Ltd Great Britain · Expires 2002-02-05 · 24y expired
What this patent protects
The present invention relates to novel acyclic ethylenediamine derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are defined as in the specification. It also re-lates to novel intermediates u…
USPTO Abstract
The present invention relates to novel acyclic ethylenediamine derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are defined as in the specification. It also re-lates to novel intermediates used in the synthesis of such derivatives. Compounds of formula (I) and their pharmaceutically acceptable salts are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.